Single-agent vinorelbine in pretreated breast cancer patients: Comparison of two different schedules

Edmondo Terzoli, C. Nisticò, A. Fabi, M. Milella, E. Bria, A. M. D'Ottavio, A. Vaccaro, B. Vanni, C. Garufi, V. Ferraresi, D. Giannarelli, P. Papaldo, P. Carlini, F. Izzo, F. Cognetti

Research output: Contribution to journalArticle

Abstract

This retrospective study compared toxicity and activity of vinorelbine according to two schedules with different projected dose intensities in heavily pretreated breast cancer patients. Forty patients were assessable for toxicity and activity in each group; group A received vinorelbine 25 mg/m2 week + lenograstim (150 μg/m2 s.c on day 3); group B received 25 mg/m2 on days 1 and 8 every 3 weeks. The projected dose intensity was 25 mg/m2/week and 16.6 mg/m2/week, and delivered dose intensity 95.2% and 94.5% in group A and B, respectively. Grade 3-4 afebrile neutropenia was recorded in 25% and 37.5% of patients in A and B, respectively. Overall response rate, 52.5% and 35%; no change, 35% and 40%; progression of disease, 12.5% and 25% in A and B, respectively. Median duration of the response was 10 months for group A and 7 months for B. Median time to progression: 9.0 months and 4.0 months for A and B, respectively. At a median follow-up of 45 months for group A and 19 months for group B, median overall survival was 19 months and 16, respectively. In conclusion the results of the study showed that dose intensity of vinorelbine could have an improvement in terms of time to progression in pretreated advanced breast cancer.

Original languageEnglish
Pages (from-to)207-213
Number of pages7
JournalJournal of Experimental and Clinical Cancer Research
Volume23
Issue number2
Publication statusPublished - Jun 2004

    Fingerprint

Keywords

  • Breast cancer
  • Dose intensity
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this